Document Detail


Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate.
MedLine Citation:
PMID:  16787876     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A 38-year-old Japanese man was referred to our hospital in June 2003 for treatment of acute respiratory failure with severe eosinophilia. Idiopathic hypereosinophilic syndrome had been diagnosed in 1994. However, karyotypic examination of bone marrow cells revealed that chromosomal translocation with t(4;10)(q12;p11) had occurred in 2000, and chronic eosinophilic leukemia was diagnosed. At admission, the patient's respiratory condition was extremely serious, and mechanical support was necessary. Despite treatment with steroid pulse therapy and cytarabine, the blood eosinophil count did not decrease, and the patient's respiratory condition worsened. After obtaining informed consent, we administered imatinib mesylate at a dose of 200 mg/day for 2 days and 100 mg/day for 3 days. The blood eosinophil count decreased dramatically over 5 days, and the patient's condition rapidly improved, such that the patient could be discharged. In this case, we performed molecular analysis using peripheral blood. The FIP1-like 1 (FIP1L1)-platelet-derived growth factor receptor alpha (PDGFRalpha) fusion transcript was found with the reverse transcriptase polymerase chain reaction analysis. In this case, eosinophilia was possibly caused by constitutive activation of tyrosine kinase produced by the FIP1L1-PDGFRalpha fusion transcript.
Authors:
Haruko Tashiro; Ryosuke Shirasaki; Mitsuho Noguchi; Moritaka Gotoh; Kazuo Kawasugi; Naoki Shirafuji
Related Documents :
16616116 - Three adults with acute lymphoblastic leukemia and dic(7;9)(p11.2;p11).
20145266 - Thromboembolic events among adult patients with primary immune thrombocytopenia in the ...
20033456 - Cyclic pollen production in cedrus deodara.
8286736 - A phase i/ii study of sequential interleukin-3 and granulocyte-macrophage colony-stimul...
2114246 - Total knee arthroplasty in classic hemophilia.
24046526 - Prone versus modified supine position in percutaneous nephrolithotomy: a prospective ra...
Publication Detail:
Type:  Case Reports; Clinical Trial; Journal Article    
Journal Detail:
Title:  International journal of hematology     Volume:  83     ISSN:  0925-5710     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-06-21     Completed Date:  2006-12-27     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  433-8     Citation Subset:  IM    
Affiliation:
Department of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Asian Continental Ancestry Group
Chromosomes, Human, Pair 10 / genetics
Chromosomes, Human, Pair 4 / genetics
Chronic Disease
Enzyme Activation / drug effects
Eosinophilia / drug therapy,  enzymology,  genetics
Follow-Up Studies
Gene Expression Regulation, Enzymologic / drug effects
Gene Expression Regulation, Leukemic / drug effects
Humans
Hypereosinophilic Syndrome / drug therapy*,  enzymology*,  genetics
Leukocyte Count
Male
Oncogene Proteins, Fusion / antagonists & inhibitors*,  biosynthesis
Piperazines / administration & dosage*
Protein Kinase Inhibitors / administration & dosage*
Pyrimidines / administration & dosage*
RNA, Messenger / biosynthesis,  genetics
RNA, Neoplasm / biosynthesis,  genetics
Receptor, Platelet-Derived Growth Factor alpha / antagonists & inhibitors*,  biosynthesis
Reverse Transcriptase Polymerase Chain Reaction / methods
Time Factors
Translocation, Genetic / genetics
mRNA Cleavage and Polyadenylation Factors / antagonists & inhibitors*,  biosynthesis
Chemical
Reg. No./Substance:
0/FIP1L1-PDGFRA fusion protein, human; 0/Oncogene Proteins, Fusion; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/RNA, Messenger; 0/RNA, Neoplasm; 0/mRNA Cleavage and Polyadenylation Factors; 152459-95-5/imatinib; EC 2.7.10.1/Receptor, Platelet-Derived Growth Factor alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rej...
Next Document:  Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysi...